In this edition...

It can be a long road to commercialise a novel biotech technology. There have been many false starts and yes things do normally take twice as long and cost four times as much. A few companies have made exceptional progress, some through M&A and others from focused activities with few setbacks. But the hard work now appears set to deliver for a number of companies that listed in 1999 and their progress will be well worth monitoring in 2008.

Elsewhere, Halcygen Pharmaceuticals' path to market looks like it will be more difficult than originally expected but the news may not all be bad for that company. And we provide a brief investment update on five other biotechs in the sector.

The editors

Companies covered: BLS, BNO, CYT, FER, GTG, HGN, PBT, POH, SPL

	Bioshares Portfolio
Year 1 (May '01 - May '02)	21.2%
Year 2 (May '02 - May '03)	-9.4%
Year 3 (May '03 - May '04)	70.0%
Year 4 (May '04 - May '05)	-16.3%
Year 5 (May '05 - May '06)	77.8%
Year 6 (May '06 - May '07)	17.3%
Year 7 (from 4 May '07)	-12.6%
Cumulative Gain	185%
Av Annual Gain (6 yrs)	26.8%

Bioshares is published by Blake Industry & Market Analysis Pty Ltd. The company also provides market and company analysis of the Australian pharmaceutical and biotech industries for local and international funds management institutions, venture capital funds and other related industry groups. For further details contact David Blake (see details below).

Blake Industry & Market Analysis Pty Ltd ACN 085 334 292 PO Box 193 Richmond Vic 3121 AFS Licence No. 258032

Enquiries for *Bioshares* Ph: (03) 9326 5382 Fax: (03) 9671 3633 Email: info@bioshares.com.au **David Blake** Ph: (03) 9326 5382 Email: blake@bioshares.com.au **Mark Pachacz**

Ph: (03) 9671 3222 Email: pachacz@bioshares.com.au

Individual Subscriptions (48 issues/year) \$320 (Inc.GST) Edition Number 244 (7 December 2007) ISSN 1443-850X

Copyright 2007 Blake Industry and Market Analysis Pty Ltd. ALL RIGHTS RESERVED. Secondary electronic transmission, photocopying, reproduction or quotation is strictly prohibited without written consent of the publisher.

Bioshares

7 December 2007 Edition 244

Delivering independent investment research to investors on Australian biotech, pharma and healthcare companies.

Class of '99 Steps Up to the Plate

The period 1999-2000 saw the biggest bull market in the global biotech sector. Driven by the excitement surrounding the sequencing of the human genome, records amount of investment flowed into the sector. In Australia in 2000, there were a record 26 new listings in the sector, which was extraordinary given there were only around 50 listed life science companies in Australia the previous year. There have been some success stories already from this pool, including Axon Instruments (sold to **Molecular Devices** in 2004) and **Sirtex Medical**. There has been some impressive progress made by others, such as **Peplin** (listed 2000) and **Chemgenex Pharmaceuticals** (relisted as Autogen in 1999). And now the next wave from the '99 biotech class are set to step up to the plate leading the next charge of aspiring Tier-1 biotechs.

Cytopia (listed 1999), **Bionomics** (listed 1999) and **Starpharma** (listed 1999 on the Austock Exempt Market) have been disappointing investments judging by their share price performance. Each are trading below their listing price aside from Bionomics, which is trading just above its 40 cent listing price. Biotech investors are told to be patient if their aim is to see the products under development reach the market. These three companies are now moving into pivotal phases of their development, with the next two years expected to deliver strong value recognition if their clinical and commercial programs deliver the results. What makes these companies worth considering is that the science behind technologies is leading edge, they are backed by strong management teams capable to keep the development on course, and they offer excellent value propositions to investors.

Cytopia

An in-depth update on Cytopia was provided in Bioshares 241. The company has an engine room for drug discovery that to date has delivered a cancer drug candidate (CYT997) that this week entered Phase II trials for the treatment of multiple myeloma. A further two Phase II trials are expected to begin next year with the same compound. The company has also signed a major drug development collaboration with **Novartis** in the area of auto-immune diseases that has a total potential deal value of \$274 million. The company has a highly respected drug discovery capability and employs approximately 50 people. With a market valuation of only \$37 million with \$14 million in cash at mid year, it is an appealing speculative investment.

Bionomics

Bionomics (see also last week's edition of Bioshares) started out as a genomics company however the model for commercial success of standalone gene-based discovery businesses went out the window very soon after the human genome was sequenced. As did **Chemgenex Pharmaceuticals**, which also had its origins as a genomics company, Bionomics has broadened its drug discovery platform through acquisition, firstly of **Neurofit** in France in 2004, then the more important acquisition of **Iliad Chemicals** in Melbourne in 2005.

Cont'd over

The Neurofit acquisition provided the company with a preclinical research team focused in central nervous system disorders, a specific area of interest for Bionomics. It has also played a key role in identifying the company's lead drug candidate for the company's second program, BNC210, for the treatment of anxiety, which is expected to move into clinical trials in a year's time.

Illiad Chemicals gave Bionomics a drug discovery platform which has delivered the company its lead compound, BNC105, a vascular disrupting agent for the treatment of solid tumours. This is now entering Phase I studies.

The next level of sophistication in trial design

There are two aspects that make the lead program noteworthy, representing the next level of sophistication in drug development. The level of preclinical testing conducted with this compound is extensive, with all results very specifically supporting the suspected method of action of this drug, whereby the vasculature network supplying tumour growth is specifically targeted whilst leaving the vasculature networks in healthy tissue untouched.

The Phase I trial, which is due to start now, has been designed, in *Bioshares* view, with a level of sophistication unseen previously in Australia and is arguably at the leading edge of oncology drug trial design. While it's a Phase I trial where the primary measure is to assess safety and establish the maximum tolerable dose, the design should deliver a barrage of information on the effect of the drug candidate on tumours.

The company will measure 10 different biomarkers to assess effects on tumour vasculature, use two different methods of imaging (DCE-MRI and CT scans), with the company bringing a US-based specialist imaging group out to Australia to train radiographers at the different trial sites to ensure results are consistent across the trial centers. The company has three trial sites set up for the trial with two back up sites, and it is incorporating an adaptive design feature into the trial, whereby if efficacy is seen in patients with a particular tumour type, then recruitment of follow-on patients will be directed towards patients will similar tumour growths.

Interim updates each quarter are expected to be reported to the market on the progress of the trial. If there are any signs this drug is taking effect, Bionomics will know very quickly, which is part of the new paradigm in cancer drug development.

Starpharma

Progress at Starpharma was slow in the early years, however recently the level of corporate and development activity has been accelerating, unbeknown to the company's share price. The business is based around the use of a novel chemistry platform, dendrimers, that allows precise chemical structures to be built that can carry active components, such as antiviral actives, on the dendrimer three dimensional scaffold.

The technology can be applied to a multitude of chemical/pharmaceutical applications that is now being shown. In 2007, the company has signed three development collaboration agreements and one licensing and supply agreement. The most significant of these agreements is the development of the company's VivaGel compound for use in condoms to prevent the transmission of sexually transmitted diseases (HIV and herpes) and also as a contraceptive.

VivaGel

VivaGel is the leading pharmaceutical application of the dendrimer technology. The company is currently conducting trials testing Vivagel as a standalone topical application for the prevention of the transmission of genital herpes and HIV. It needs to be acknowledged that there is major unmet need for an effective agent to prevent the transmission of sexually transmitted diseases. There is also a paucity in the development pipeline of effective topical candidates to prevent the spread of STDs which also places Starpharma in a solid position.

Starpharma is currently working through small safety studies with Vivagel ahead of major efficacy studies expected to begin in 2008. For herpes, a trial involving an estimated 1800 people will be required which will be conducted in the US and in some parts of Africa. For HIV, around 3000 trial participants will be required in trials that will be conducted in Africa and other regions. The more immediate commercial focus for the company is for the use of VivaGel with condoms.

Major commercial focus - condom deals

Starpharma has signed development deals with two major condom manufacturers this year that is expected to see Vivagel on the market within three years. The condom market is valued at US\$3.2 billion in major western markets, with **SSL International** having between 30%-35% market share. In October this year Starpharma signed a development agreement with SSL, which owns the Durex brand of condoms.

An effective antimicrobicide (and possible contraceptive) can generate up to a 50% pricing increase for condoms and may become an important differentiator for SSL for its products. The deal with SSL is exclusive. With about 30%-40% of condoms sold (in the US) previously having been coated with microbicides, such as Nonoxinol-9 which has now failed to show efficacy, it represents a potential market for SSL of at least US\$400 million, before price premiums, for VivaGel coated condoms and assumes the company does not increase market share. The royalty Starpharma has negotiated is unknown, but even at 5% (*Bioshares* estimate), it represents a potential future royalty to Starpharma of US\$20 million a year.

The other collaborative development agreement signed in the condom area was with an undisclosed manufacturer that is a leading seller of condoms into under-developed countries. This a region specific deal, outside of the regions under which the SSL deal covers.

Stiefel Collaboration

This week Starpharma announced a collaboration with Stiefel Laboratories, a major pharmaceutical company that specializes in der-

matology and sells products into over 100 countries. The collaboration will investigate the use of dendrimers as carriers for dermatology products, to allow more sustained release of the active agents into the skin. The collaboration will initially look at two compounds and may be extended to cover other Stiefel products.

EMD Biosciences collaboration

Earlier this year, Starpharma signed a license and supply agreement with the chemical reagents company, **EMD Biosciences**, through the Starpharma subsidiary in the US, **Dendritic Nanotechnologies**. EMD will begin selling (this month) Starpharma's transfection agents for research purposes only that allow siRNA to transfect cells.

The market is worth US\$200 million a year and there is a very high demand for vehicles that effectively help siRNA transfect into cells. It will be worth monitoring the demand for the Starpharma product in this area.

There is an even higher demand for delivering siRNA *in vivo* as a therapeutic agent. Starpharma is currently is discussion with potential partners that may seek to license this technology on a non-exclusive basis. If the technology, called Priostar, is effective *in vivo*, it is potentially a very valuable product for Starpharma, where

the company could expect royalty rights from the development of successful siRNA therapeutics that incorporate the Priostar delivery technology.

Summary

Drug discovery and development is a long and difficult process. Some companies have been successful in accelerating commercialization through acquisition of later stage pipelines, such as Chemgenex Pharmaceuticals, or have been adept at focusing the development of a single drug candidate to ensure rapid progression through the drug development process, such as Peplin. Others, such as Cytopia, Bionomics and Starpharma have had delays and setbacks. However a common link with all three of these companies is that they appear to be ready to deliver on critical clinical and commercial milestones over the next one to two years that may see the companies as the next wave of Tier-1 Australian biotechs.

Bioshares recommendations: Cytopia: **Speculative Buy Class A** Bionomics: **Speculative Buy Class A** Starpharma: **Speculative Buy Class A**

Bioshares

Halcygen Pharmaceuticals – Mixed Outcome From FDA Meeting

Halcygen Pharmaceuticals (HGN: \$0.425) recently announced the outcome of an important trial protocol meeting with the FDA for its lead drug candidate, Subazole. The company is developing a range of supergeneric compounds it has in-licensed from **Mayne Pharma International** (now **Hospira**). Subazole is being developed as an improved version of Sporanox (itraconazole), an off patent antifungal drug that generates annual sales in excess of US\$600 million. The outcome of the meeting is that Halcygen will be required to conduct a more extensive Phase III study than originally anticipated. This presents both some disadvantages and benefits for the company.

Halcygen's lead drug candidate

Halcygen has in-licensed what it believes to be an improved formulation of Sporanox, that may deliver an improved absorption profile as well as a preferred patient usage protocol. Sporanox (and generic versions) are currently used twice daily for fungal infections and need to be taken with a high fat food meal. Halcygen's version has shown in pharmacokinetic studies that its version of itraconazole can deliver the same amount of active drug into the blood stream at half the dose, thereby potentially reducing side effects of the drug,

Outcome of FDA meeting

Halcygen had originally anticipated conducting only a 200 person pharmacokinetic trial in the US, which was to show that equivalent levels of the active drug (itraconazole) reach the blood stream. Following the meeting with the FDA, Halcygen will be required to conduct a larger Phase III study (the company estimates about 350 people) to show its drug is bioequivalent, that its drug is safer, and also potentially investigate whether its version can be delivered in lower doses to achieve a similar blood level of the drug in patients.

The company will continue with the 505b(2) route through the FDA, which means only one Phase III study will be required. It can use data previously filed on itraconazole by others to receive approval for its drug candidate, and drug-drug interactions do not need to be investigated. In the Phase III trial, Halcygen will compare its Subazole with generic itraconazole, delivered twice daily to patients after food, and it will also be compared against a placebo. Halcygen is also likely to need to conduct a pharmacokinetic study in about 50 people, possibly prior to the Phase III study. The company will need to meet with the FDA once again before the Phase III trial commences, this time with the dermatology division rather than the anti-infectives division.

Competitors

That there are competitors developing other versions of itraconazole justifies the approach Halcygen is taking. One competitor, **Barrier Therapeutics** in the US, has just completed enrolment of a Phase III trial of a once a day itraconazole 200 mg dose (Sporanox is delivered twice daily at 100mg per dose) in precisely the same indication that Halcygen is proceeding with, an onychomycosis fungal infection of the toe-nail.

Barrier Therapeutics accessed its version of itraconzaole, which is manufactured through a melt extrusion process, from the company that developed Sporanox, Janssen (Johnson & Johnson). Barrier had an agreement with Janssen to develop this potentially improved form to treat candidiasis although that trial failed and *Cont'd over*

Halcygen cont'd

Barrier retained the rights to the itraconazole version for other fungal infections.

In the third quarter of 2006, Barrier started a 1370 patient trial which took just over 12 months to complete enrollment, which occurred at the end of September this year. The trial appears to be similar in duration to the planned Halcygen Phase III trial with patients being treated for three months and monitored for a further nine months.

Halcygen expects its trial will start in the second quarter of 2008 and to be finished by mid 2009. These timelines are reasonable if the trial starts on time and if patient numbers are around 350. Judging by the Barrier trial, enrollment is less difficult (and less expensive) than for enrolling patients for a new drug trial in a more threatening disease area. However if the trial size needs to be increased similar to the current Barrier trial then this timeline may move out further.

Positive outcomes

Although Halcygen will need to conduct a larger and more onerous Phase III study, the benefits from a positive trial outcome are that its drug will be given greater claims over generic versions i.e. that its drug is a safer version and possibly the dosage required is less. This will give it a clear differentiation over generic versions, and may also allow the company to charge a premium.

On the downside, whilst Halcygen's Subazole may deliver an improved safety aspect, the Barrier product, if successful, will be dosed only once a day, as opposed to twice daily for Subazole. It is likely follow-on trials may investigate Subazole as a once-aday dose.

A potentially surprising upside

Another development with itraconazole is worth mentioning. The Johns Hopkins University School of Medicine earlier this year found that itraconazole may be an effective angiogenesis inhibitor. It is a surprising finding but one that may have a positive impact, although not in the short term, on the itraconzole market.

Summary

Although the news may not have all been good for Halcygen following its recent FDA protocol meeting, there is a clear health outcome argument for developing a safer version of itraconazole, a point that is not likely to be lost on the FDA. The presence of competitors is positive from the viewpoint that it's a market worth investing funds into, and it does not appear to be a straightforward process to develop improved versions of Sporanox, and to bring such products to market. The timelines have been moved out for Halcygen although the company believes it has the funds to get its lead program through to the end of its Phase III trial with just under \$14 million in the bank at the end of September. The next critical milestones for Halcygen will be results from further pharmacokinetic studies and the outcome of its next meeting with the Dermatology Division of the FDA.

Bioshares recommendation: Speculative Hold Class B

Bioshares

Company	Price (current)	Price added to	Date added
		portfolio	
Bionomics	0.415	0.415	December 2007
Cogstate	0.135	0.13	November 2007
Ventracor	\$0.66	\$0.625	October 2007
Sirtex Medical	\$4.72	\$3.90	October 2007
Clinuvel Pharmaceuticals	\$0.39	\$0.66	September 2007
Progen Pharmaceuticals	\$2.52	\$3.52	September 2007
Starpharma Holdings	\$0.36	\$0.37	August 2007
Pharmaxis	\$4.17	\$3.15	August 2007
Universal Biosensors	\$1.55	\$1.23	June 2007
Biota Holdings	\$1.32	\$1.55	March 2007
Tissue Therapies	\$0.45	\$0.58	February 2007
Probiotec	\$1.40	\$1.12	February 2007
Phylogica	\$0.23	\$0.42	January 2007
Peplin Inc	\$0.79	\$0.83	January 2007
Arana Therapeutics	\$1.17	\$1.31	October 2006
Sunshine Heart	\$0.16	\$0.19	September 2006
Chemgenex Pharma.	\$1.01	\$0.38	June 2006
Cytopia	\$0.50	\$0.46	June 2005
Optiscan Imaging	\$0.27	\$0.35	March 2005
Acrux	\$1.35	\$0.83	November 2004
Alchemia	\$0.71	\$0.67	May 2004

Portfolio Changes – 7 Dec 2007

IN:

Bionomics has been added at 41.5 cents.

OUT:

No changes.

Bioshares Five Stock Wrap

Company	Biolayer	Code	BLS	СМР	\$0.08	Cap'n (\$M)	\$6.0	Cash (\$M)	\$1.05	SI	1	1.1
BLS has de	eveloped a chemistry pla			-								
	logy, in theory, offers co			•	•	•						
	nder-performed since its	-				•		•	firms			
	as shifted to include deve		Ū	Ŭ		•		0	, 111115			
	05/07, for a US client, B	-	-						by 10-fold			
	BLS expects to complete								by 10-101a			
	· ·				U U				in blood			
	of a blood-based Alzhein				,			,	IN DIOOD			
	lower than expected pro	•	<u> </u>	technolog	gy with multi							
Biosnares re	ecommendation: Specul	lative Buy C	lass B			Timing Consider	ations - N	lone				
Company	Genetic Technologies	Code	GTG	СМР	\$0.155	Cap'n (\$M)	\$56.2	Cash (\$M)	\$16.28	SI	N	I.A
	ates a DNA testing service						φ00.2		ψ10.20			
), Michael Ohannesian,		-		-	-	was annoi	nted in Sentember				
	n played a significant rol				• ·	-		-	atoqu			
				•	-			-		10		
	GTG to add new produc	-		-	-			-		10		
	nder Dr Mervyn Jacobse				-	· ·	-	In Issue for the boa	ua			
	Quarterly cash flow sta	litements to b	e monito	rea for sig	uns that effic	siencies are being	achieved					
	n of new tests	alaa 1 1			ala a da da	TO	1.4. · · ·					
	/ith a new CEO at the h			essive tra	ick record, G	1						
Bioshares re	ecommendation: Specul	lative Hold (Class B			Timing Consider	rations - S	hare register rebala	ance pivota			
-			DDT		A0 0		* (0 0		* • • • •			
Company	Prana Biotech	Code	PBT	СМР	\$0.27	Cap'n (\$M)	\$49.0	Cash (\$M) est.	\$16.0	SI	1	1.7
 PBT is developed 	eloping a drug PBT-2, a	metal attenu	lating col	mpound, t	to treat Alzh	eimers disease.						
 PBT has di 	sappointed before with o	development	of PBT-	1 halted b	ecause of m	anufacturing imp	urities (di-i	odo-8-hydroxyquin	oline)			
 However Pl 	BT-2 is a cleaner drug; ı	recent PII sa	fety mon	itoring rep	ort said "no	emergent pattern	of unwant	ed adverse events	' was obse	rved		
The current	t Phase II trial is being c	onducted in	Sweden;	if succes	sful, a US c	levelopment (regu	latory) pla	n will need to be sp	elt out			
 Issue - sub 	stantial options/warrants	s (~60m) rem	nain outs	tanding w	ith PBT; full	y diluted cap'n is	\$65 millior	1				
Milestone -	Phase IIa results expec	ted Q1 2008	;									
Comment: P	Comment: PBT offers a clear-cut short-term trial results trading opportunity; if results are unambigous expect a major transformation											
Bioshares recommendation: Speculative Buy Class C Timing Considerations - buy and sell before trial result ann.							igous expe	ect a major transfor	mation			
Bioshares re				rading opp	oortunity; if r	I	•	-		nn.		
Bioshares re				rading opp	oortunity; if r	I	•	-		nn.		
Bioshares re Company				CMP	portunity; if r	I	ations - bu	-		nn.	3	3.3
Company	ecommendation: Specul	lative Buy C	FER	СМР	\$1.07	Timing Consider	ations - bu \$153.4	Ly and sell before tr Cash (\$M)	ial result a		3	3.3
Company • FER is dev	ecommendation: Specul	Code	FER FER	CMP / based or	\$1.07 n X-ray diffra	Timing Consider Cap'n (\$M) action in conjuncti	\$153.4 on with sy	Cash (\$M)	ial result a		3	3.3
Company FER is devi The theory 	ecommendation: Specul Fermiscan Holdings eloping a breast cancer	Code Screening te iates x-ray di	FER FER chnology	CMP / based or patterns t	\$1.07 n X-ray diffra taken from h	Timing Consider Cap'n (\$M) action in conjuncti air samples with	\$153.4 on with synthe occurrent	Cash (\$M) Cash (activities anchotron facilities ance of cancer	ial result a		3	3.3
Company • FER is dev • The theory • FER is run	Fermiscan Holdings Fermiscan Holdings eloping a breast cancer of the technology assoc ning a 2000 patient valid	Code Screening te iates x-ray di lation study;	FER FER chnology iffraction	CMP / based or patterns t	\$1.07 n X-ray diffra taken from h n 500 subje	Timing Consider Cap'n (\$M) action in conjuncti air samples with cts were reported	\$153.4 on with synthesis of the second on August	Cash (\$M) Cash (\$M) nchotron facilities ence of cancer	ial result a		3	3.3
Company • FER is deve • The theory • FER is runn • 10/14 pts w	Fermiscan Holdings eloping a breast cancer of the technology assoc ning a 2000 patient valid vere correctly identified a	Code Code screening te iates x-ray di lation study; as having bre	FER FER inchnology iffraction interim re east cance	CMP / based or patterns t esults fror :er; 4 were	\$1.07 n X-ray diffra taken from h n 500 subjer e missed du	Timing Consider Cap'n (\$M) action in conjuncti air samples with cts were reported e to hair chemical	\$153.4 on with sy the occurre in August treatmen	Cash (\$M) Cash (\$M) nchotron facilities ence of cancer	ial result a		3	3.3
Company • FER is deve • The theory • FER is runn • 10/14 pts w • Hair coloura	Fermiscan Holdings eloping a breast cancer of the technology assoc ning a 2000 patient valid vere correctly identified a ation is widespread and	Code Code screening te iates x-ray di dation study; as having bre an inability to	FER FER chnology iffraction interim re east cance o distingi	CMP / based or patterns t esults fror er; 4 were sh chemic	\$1.07 n X-ray diffra taken from h n 500 subjet e missed du cally treated	Timing Consider Cap'n (\$M) action in conjuncti air samples with cts were reported e to hair chemical hair may be a neg	\$153.4 on with synthe occurrent in August treatmen gative for th	Cash (\$M) Cash (\$M) nchotron facilities ence of cancer t te FER business	ial result a		3	3.3
Company • FER is deve • The theory • FER is runn • 10/14 pts w • Hair coloura • Another neg	Fermiscan Holdings eloping a breast cancer of the technology assoc ning a 2000 patient valid vere correctly identified a ation is widespread and gative for FER is its relia	Code Screening te iates x-ray di lation study; as having bre an inability to ance on dedi	FER chnology iffraction interim re east cance o distingisticated bea	CMP / based or patterns t esults from eer; 4 were sh chemic am lines; 5	\$1.07 h X-ray diffra taken from h n 500 subje e missed du cally treated synchotrons	Timing Consider Cap'n (\$M) action in conjuncti air samples with cts were reported e to hair chemical hair may be a neg require significar	\$153.4 on with synthe occurrent in August treatmen gative for the	Cash (\$M) Cash (\$M) Inchotron facilities ence of cancer t t ne FER business e for maintenance	ial result a		3	3.3
Company • FER is devi- • The theory • FER is runn • 10/14 pts w • Hair coloura • Another nea • In our view	Fermiscan Holdings eloping a breast cancer of the technology assoc ning a 2000 patient valid vere correctly identified a ation is widespread and gative for FER is its relia <i>i</i> it is not certain that the	Code screening te iates x-ray di lation study; as having bre an inability to ance on dedii FER techno	FER Choology	CMP / based or patterns t esults fror er; 4 were sh chemic am lines; s uniquely i	\$1.07 h X-ray diffra taken from h n 500 subje e missed du cally treated synchotrons identify canc	Timing Consider Cap'n (\$M) action in conjuncti air samples with cts were reported e to hair chemical hair may be a neg require significar sers by tissue type	\$153.4 on with synthe occurrent in August treatmen gative for the the downtimes; hence m	Cash (\$M) Cash (\$M) Inchotron facilities ence of cancer t te FER business e for maintenance iore studies may be	ial result a		3	3.3
Company • FER is deve • The theory • FER is runn • 10/14 pts w • Hair coloura • Another neg • In our view • Milestones:	Fermiscan Holdings eloping a breast cancer of the technology assoc ning a 2000 patient valid vere correctly identified a ation is widespread and gative for FER is its relia v it is not certain that the FER expects validation	Code Screening te iates x-ray di lation study; as having bre an inability to ance on dedii FER techno trials to be c	FER chnology iffraction interim re east cance b distingis cated bea logy can complete	CMP / based or patterns t esults fror er; 4 were sh chemic am lines; s uniquely i end 2007	\$1.07 n X-ray diffra taken from h n 500 subject e missed dur cally treated synchotrons identify cance '; there is a l	Timing Consider Cap'n (\$M) action in conjuncti air samples with cts were reported e to hair chemical hair may be a neg require significar ers by tissue type ikelihood this mile	\$153.4 on with synthe occurrent in August treatmen gative for the to downtimes; hence me stone will	Cash (\$M) Cash (\$M) nchotron facilities ence of cancer t he FER business e for maintenance iore studies may be not be met	ial result a		3	3.3
Company • FER is deve • The theory • FER is runn • 10/14 pts w • Hair coloura • Another neg • In our view • Milestones: Comment: D	Fermiscan Holdings eloping a breast cancer of the technology assoc ning a 2000 patient valid vere correctly identified a ation is widespread and gative for FER is its relia vit is not certain that the FER expects validation eveloping a screening te	Code Screening te iates x-ray di lation study; as having bre an inability to ance on dedii FER techno trials to be c	FER chnology iffraction interim re east cance b distingis cated bea logy can complete	CMP / based or patterns t esults fror er; 4 were sh chemic am lines; s uniquely i end 2007	\$1.07 n X-ray diffra taken from h n 500 subject e missed dur cally treated synchotrons identify cance '; there is a l	Timing Consider Cap'n (\$M) action in conjuncti air samples with cts were reported e to hair chemical hair may be a neg require significar ers by tissue type ikelihood this mile dical practise is e	\$153.4 on with synthe occurrent in August treatmen gative for the tot downtimes; hence me stone will cceedingly	Cash (\$M) Cash (\$M) nchotron facilities ence of cancer t ne FER business e for maintenance ore studies may be not be met ambitious	ial result a		3	3.3
Company • FER is deve • The theory • FER is runn • 10/14 pts w • Hair coloura • Another neg • In our view • Milestones: Comment: D	Fermiscan Holdings eloping a breast cancer of the technology assoc ning a 2000 patient valid vere correctly identified a ation is widespread and gative for FER is its relia v it is not certain that the FER expects validation	Code Screening te iates x-ray di lation study; as having bre an inability to ance on dedii FER techno trials to be c	FER chnology iffraction interim re east cance b distingis cated bea logy can complete	CMP / based or patterns t esults fror er; 4 were sh chemic am lines; s uniquely i end 2007	\$1.07 n X-ray diffra taken from h n 500 subject e missed dur cally treated synchotrons identify cance '; there is a l	Timing Consider Cap'n (\$M) action in conjuncti air samples with cts were reported e to hair chemical hair may be a neg require significar ers by tissue type ikelihood this mile	\$153.4 on with synthe occurrent in August treatmen gative for the tot downtimes; hence me stone will cceedingly	Cash (\$M) Cash (\$M) nchotron facilities ence of cancer t ne FER business e for maintenance ore studies may be not be met ambitious	ial result a		3	3.3
Company • FER is deve • The theory • FER is runn • 10/14 pts w • Hair coloura • Another neg • In our view • Milestones: Comment: D Bioshares re	Fermiscan Holdings eloping a breast cancer of the technology assoc ning a 2000 patient valid vere correctly identified a ation is widespread and gative for FER is its relia v it is not certain that the FER expects validation eveloping a screening te ecommendation: Sell	Code screening te iates x-ray di lation study; as having bre an inability te ance on dedie FER techno trials to be c echnology ex	FER chnology iffraction interim re east cance o distingio cated bea logy can complete clusive o	CMP / based or patterns t esults fror :er; 4 were sh chemic am lines; : uniquely i end 2007 f evidence	\$1.07 h X-ray diffra taken from h n 500 subjet e missed du cally treated synchotrons identify cance r; there is a l e-based med	Timing Consider Cap'n (\$M) action in conjuncti air samples with cts were reported the to hair chemical hair may be a neg require significar cers by tissue type ikelihood this mile tical practise is ex Timing Consider	\$153.4 on with synthe occurrent in August treatmen gative for the tot downtime is hence me stone will ceedingly rations - N	Ly and sell before tr Cash (\$M) Inchotron facilities ence of cancer t t te FER business e for maintenance iore studies may be not be met ambitious lone	ial result a \$22.6 e required	SI		
Company • FER is deve • The theory • FER is runn • 10/14 pts w • Hair coloura • Another neg • In our view • Milestones: Comment: D Bioshares re Company	Fermiscan Holdings eloping a breast cancer of the technology assoc ning a 2000 patient valid vere correctly identified a ation is widespread and gative for FER is its relia v it is not certain that the FER expects validation eveloping a screening te ecommendation: Sell Phosphagenics	Code screening te iates x-ray di lation study; as having bre an inability to ance on dedi FER techno trials to be o echnology ex Code	FER chnology iffraction interim re east cance o distingi- cated bea logy can complete clusive o	CMP / based or patterns t esults fror er; 4 were sh chemic am lines; s uniquely i end 2007 f evidence	\$1.07 h X-ray diffra taken from h n 500 subje e missed du cally treated synchotrons identify cance '; there is a l e-based med \$0.23	Timing Consider Cap'n (\$M) action in conjuncti air samples with cts were reported to hair chemical hair may be a neg require significar ers by tissue type ikelihood this mile dical practise is er Timing Consider Cap'n (\$M)	\$153.4 on with synthe occurrent in August treatmen gative for the tot downtim e; hence m estone will cceedingly rations - N \$143.5	Cash (\$M) Cash (\$M) nchotron facilities ence of cancer t t e FER business e for maintenance iore studies may be not be met ambitious lone Cash (\$M)	ial result a			3.3
Company • FER is devi- • The theory • FER is runn • 10/14 pts w • Hair coloura • Another neg • In our view • Milestones: Comment: D Bioshares ref Company • POH is con	Fermiscan Holdings eloping a breast cancer of the technology assoc ning a 2000 patient valid vere correctly identified a ation is widespread and gative for FER is its relia vit is not certain that the FER expects validation eveloping a screening to ecommendation: Sell Phosphagenics nmercialising tocopeher	Code screening te iates x-ray di lation study; as having bre an inability te ance on dedii FER techno trials to be of echnology ex Code ol (phosphor	FER chnology iffraction interim re east cance o distingi- cated be- logy can complete clusive o	CMP / based or patterns t esults fror er; 4 were sh chemic am lines; s uniquely i end 2007 f evidence CMP amin E) ir	\$1.07 h X-ray diffra taken from h n 500 subje e missed du cally treated synchotrons identify cance '; there is a l e-based meet \$0.23 h drug delive	Timing Consider Cap'n (\$M) action in conjuncti air samples with cts were reported the to hair chemical hair may be a neg require significar ers by tissue type ikelihood this miled tical practise is ex Timing Consider Cap'n (\$M) ry, cosmetics, an	\$153.4 on with synthe occurrent in August treatmen gative for the treatmen gative for the tot downtim es; hence m stone will ceedingly ations - N \$143.5 d nutraceu	And Sell before tr Cash (\$M) nchotron facilities ence of cancer t t t FER business e for maintenance ore studies may be not be met ambitious lone Cash (\$M) ticals	ial result a \$22.6 e required \$16.30	SI S.I		
Company • FER is devi- • The theory • FER is runn • 10/14 pts w • Hair coloura • Another nea • In our view • Milestones: Comment: D Bioshares re Company • POH is con • Completed	Fermiscan Holdings eloping a breast cancer of the technology assoc ning a 2000 patient valid vere correctly identified a ation is widespread and gative for FER is its relia r it is not certain that the FER expects validation eveloping a screening te commendation: Sell Phosphagenics mmercialising tocopeher Ph. I trial for TPM Insuli	Code screening te iates x-ray di lation study; as having bre an inability to ance on dedii FER techno trials to be o echnology ex Code ol (phosphor in (Aug); con	FER chnology iffraction interim re east cance o distingis cated bea logy can complete clusive o POH ylated vit nmencec	CMP / based or patterns t esults fror er; 4 were sh chemic am lines; : uniquely i end 2007 f evidence CMP amin E) ir t Ph. I tria	\$1.07 h X-ray diffra taken from h n 500 subje e missed du cally treated synchotrons identify cance (; there is a l e-based med \$0.23 h drug delive I TPM oxyco	Timing Consider Cap'n (\$M) action in conjuncti air samples with cts were reported the to hair chemical hair may be a neg require significar require significar ters by tissue type kelihood this mile dical practise is ex Timing Consider Cap'n (\$M) ory, cosmetics, an done (pain) (Sep	\$153.4 on with synthe occurrent in August treatmen gative for the treatmen gative for the tot downtim es; hence m stone will ceedingly ations - N \$143.5 d nutraceu	And Sell before tr Cash (\$M) nchotron facilities ence of cancer t t t FER business e for maintenance ore studies may be not be met ambitious lone Cash (\$M) ticals	ial result a \$22.6 e required \$16.30	SI S.I		
Company • FER is deve • The theory • FER is runn • 10/14 pts w • Hair coloura • Another neg • In our view • Milestones: Comment: D Bioshares re Company • POH is con • Completed • Nestle is fu	Fermiscan Holdings eloping a breast cancer of the technology assoc ning a 2000 patient valid vere correctly identified a ation is widespread and gative for FER is its relia r it is not certain that the FER expects validation eveloping a screening te ecommendation: Sell Phosphagenics nmercialising tocopeher Ph. I trial for TPM Insuli unding a Ph.II trial of Pho	Code screening te iates x-ray di lation study; as having bre an inability te ance on dedic FER techno trials to be o echnology ex Code ol (phosphor in (Aug); con ospa E in the	FER chnology iffraction interim re east cance o distingio cated bea logy can complete clusive o POH ylated vit nmencece manage	CMP / based or patterns t esults from er; 4 were sh chemic am lines; : uniquely i end 2007 f evidence CMP amin E) ir Ph. I tria ment of m	\$1.07 h X-ray diffra taken from h n 500 subjec e missed du cally treated synchotrons identify cance ; there is a l e-based med \$0.23 h drug delive I TPM oxyco netabolic syr	Timing Consider Cap'n (\$M) action in conjuncti air samples with cts were reported to hair chemical hair may be a neg require significar ters by tissue type ikelihood this mile dical practise is ex Timing Consider Cap'n (\$M) ry, cosmetics, an odone (pain) (Sep adrome	\$153.4 on with synthe occurrent in August treatmen gative for the tot downtim e; hence m stone will ceedingly ations - N \$143.5 d nutraceut t); comment	Cash (\$M) nchotron facilities ence of cancer t te FER business e for maintenance for e studies may be not be met ambitious lone Cash (\$M) tticals nced Ph II TPM ins	ial result a \$22.6 e required \$16.30	SI S.I		
Company • FER is deve • The theory • FER is runn • 10/14 pts w • Hair coloura • Another neg • In our view • Milestones: Comment: D Bioshares re Company • POH is con • Completed • Nestle is fu	Fermiscan Holdings eloping a breast cancer of the technology assoc ning a 2000 patient valid vere correctly identified a ation is widespread and gative for FER is its relia r it is not certain that the FER expects validation eveloping a screening te commendation: Sell Phosphagenics mmercialising tocopeher Ph. I trial for TPM Insuli	Code screening te iates x-ray di lation study; as having bre an inability te ance on dedic FER techno trials to be o echnology ex Code ol (phosphor in (Aug); con ospa E in the	FER chnology iffraction interim re east cance o distingio cated bea logy can complete clusive o POH ylated vit nmencece manage	CMP / based or patterns t esults from er; 4 were sh chemic am lines; : uniquely i end 2007 f evidence CMP amin E) ir Ph. I tria ment of m	\$1.07 h X-ray diffra taken from h n 500 subjec e missed du cally treated synchotrons identify cance ; there is a l e-based med \$0.23 h drug delive I TPM oxyco netabolic syr	Timing Consider Cap'n (\$M) action in conjuncti air samples with cts were reported to hair chemical hair may be a neg require significar ters by tissue type ikelihood this mile dical practise is ex Timing Consider Cap'n (\$M) ry, cosmetics, an odone (pain) (Sep adrome	\$153.4 on with synthe occurrent in August treatmen gative for the tot downtim e; hence m stone will ceedingly ations - N \$143.5 d nutraceut t); comment	Cash (\$M) nchotron facilities ence of cancer t te FER business e for maintenance for e studies may be not be met ambitious lone Cash (\$M) tticals nced Ph II TPM ins	ial result a \$22.6 e required \$16.30	SI S.I		
Company • FER is devi- • The theory • FER is runn • 10/14 pts w • Hair coloura • Another neg • In our view • Milestones: Comment: D Bioshares re Company • POH is con • Completed • Nestle is fu • Lack of new	Fermiscan Holdings eloping a breast cancer of the technology assoc ning a 2000 patient valid vere correctly identified a ation is widespread and gative for FER is its relia r it is not certain that the FER expects validation eveloping a screening te ecommendation: Sell Phosphagenics nmercialising tocopeher Ph. I trial for TPM Insuli unding a Ph.II trial of Pho	Code screening te iates x-ray di dation study; as having bre an inability te ance on dedie FER techno trials to be o echnology ex Code ol (phosphor in (Aug); com ospa E in the ement (11/12)	FER chnology iffraction interim re east cance o distingi- cated bea logy can cated bea logy can cated bea logy can clusive o POH ylated vit nmencece e manage 2/05) with	CMP / based or patterns t esults fror eer; 4 were sh chemic am lines; : uniquely i end 2007 f evidence CMP amin E) ir Ph. I tria ment of m h drug del	\$1.07 h X-ray diffra taken from h n 500 subjec e missed du cally treated synchotrons identify cance r; there is a l e-based med \$0.23 h drug delivec I TPM oxycco netabolic syr ivery compa	Timing Consider Cap'n (\$M) action in conjuncti air samples with cts were reported the to hair chemical hair may be a neg require significar cers by tissue type ikelihood this mile dical practise is ex Timing Consider Cap'n (\$M) ery, cosmetics, an adone (pain) (Sep adrome ny ALZA is not a	\$153.4 on with synthe occurrent in August treatmen gative for the tot downtim e; hence m stone will ceedingly ations - N \$143.5 d nutraceut t); comment	Cash (\$M) nchotron facilities ence of cancer t te FER business e for maintenance for e studies may be not be met ambitious lone Cash (\$M) tticals nced Ph II TPM ins	ial result a \$22.6 e required \$16.30	SI S.I		
Company • FER is devi- • The theory • FER is runn • 10/14 pts w • Hair coloura • Another neg • In our view • Milestones: Comment: D Bioshares re Company • POH is con • Completed • Nestle is fu • Lack of new • Orbis Globa	Fermiscan Holdings eloping a breast cancer of the technology assoc ning a 2000 patient valid vere correctly identified a ation is widespread and gative for FER is its relia v it is not certain that the FER expects validation eveloping a screening te ecommendation: Sell Phosphagenics nmercialising tocopehen Ph. I trial for TPM Insuli inding a Ph.II trial of Pho vsflow on research agre	Code screening te iates x-ray di lation study; as having bre an inability te ance on dedie FER techno trials to be o echnology ex Code ol (phosphor in (Aug); con ospa E in the ement (11/12 5.2 % stake	FER chnology iffraction interim re east cance o distingis cated bea logy can complete clusive o POH ylated vit nmencece manage 2/05) with in POH	CMP / based or patterns t esults fror :er; 4 were sh chemic am lines; : uniquely i end 2007 f evidence CMP amin E) ir t Ph. I tria ment of m n drug del (up from 7	\$1.07 h X-ray diffra taken from h n 500 subjet e missed du- cally treated synchotrons identify cance r; there is a l e-based med \$0.23 h drug delivet I TPM oxycometabolic syr ivery compa 7.5% 14/11//	Timing Consider Cap'n (\$M) action in conjuncti air samples with cts were reported the to hair chemical hair may be a neg require significar ers by tissue type ikelihood this mile dical practise is ex Timing Consider Cap'n (\$M) ry, cosmetics, an odone (pain) (Sep ndrome ny ALZA is not a 25)	\$153.4 on with synthe occurrent in August treatmen gative for the treatmen gative for the to downtim e; hence m stone will cceedingly rations - N \$143.5 d nutraceut); comment positive sign	Cash (\$M) nchotron facilities ence of cancer t te FER business e for maintenance for e studies may be not be met ambitious lone Cash (\$M) tticals nced Ph II TPM ins	ial result a \$22.6 e required \$16.30	SI S.I		
Company • FER is devi- • The theory • FER is runn • 10/14 pts w • Hair coloura • Another neg • In our view • Milestones: Comment: D Bioshares ref Company • POH is con • Completed • Nestle is fu • Lack of new • Orbis Globa	Fermiscan Holdings eloping a breast cancer of the technology assoc ning a 2000 patient valid vere correctly identified a ation is widespread and gative for FER is its relia v it is not certain that the FER expects validation eveloping a screening te accommendation: Sell Phosphagenics nmercialising tocopehen Ph. I trial for TPM Insuli inding a Ph.II trial of Pho vsflow on research agre al Equity Fund holds a 1	Code screening te iates x-ray di lation study; as having bre an inability te ance on dedii FER techno trials to be of echnology ex Code ol (phosphor in (Aug); con ospa E in the ement (11/12 5.2 % stake nsulin in H1 2	FER chnology iffraction interim re east cance o distingi- cated bea logy can complete clusive o POH ylated vit nmencec manage 2/05) with in POH 2008; col	CMP / based or patterns t esults fror :er; 4 were sh chemic am lines; : uniquely i end 2007 f evidence CMP amin E) ir t Ph. I tria ment of m n drug del (up from 7	\$1.07 h X-ray diffra taken from h n 500 subjet e missed du- cally treated synchotrons identify cance r; there is a l e-based med \$0.23 h drug delivet I TPM oxycometabolic syr ivery compa 7.5% 14/11//	Timing Consider Cap'n (\$M) action in conjuncti air samples with cts were reported the to hair chemical hair may be a neg require significar ers by tissue type ikelihood this mile dical practise is ex Timing Consider Cap'n (\$M) ry, cosmetics, an odone (pain) (Sep ndrome ny ALZA is not a 25)	\$153.4 on with synthe occurrent in August treatmen gative for the treatmen gative for the to downtim e; hence m stone will cceedingly rations - N \$143.5 d nutraceut); comment positive sign	Cash (\$M) nchotron facilities ence of cancer t te FER business e for maintenance for e studies may be not be met ambitious lone Cash (\$M) tticals nced Ph II TPM ins	ial result a \$22.6 e required \$16.30	SI S.I		
Company • FER is devi- • The theory • FER is runn • 10/14 pts w • Hair coloura • Another neg • In our view • Milestones: Comment: D Bioshares ref Company • POH is con • Completed • Nestle is fu • Lack of new • Orbis Globa • Milestones: • Filing of INI	Fermiscan Holdings eloping a breast cancer of the technology assoc ning a 2000 patient valid vere correctly identified a ation is widespread and gative for FER is its relia rit is not certain that the FER expects validation eveloping a screening to ecommendation: Sell Phosphagenics nmercialising tocopeher Ph. I trial for TPM Insuli unding a Ph.II trial of Pho vsflow on research agre al Equity Fund holds a 1 complete Ph. II TPM Ir Ds for TPM insulin and	Code screening te iates x-ray di lation study; as having bre an inability te ance on dedii FER techno trials to be of echnology ex Code ol (phosphor in (Aug); con ospa E in the ement (11/12 5.2 % stake nsulin in H1 2	FER chnology iffraction interim re east cance o distingi- cated bea logy can complete clusive o POH ylated vit nmencec amanage 2/05) witt in POH 2008; con ne	CMP / based or patterns t esults from er; 4 were sh chemic am lines; s uniquely i end 2007 f evidence CMP amin E) ir d Ph. I tria ment of m h drug del (up from 7 mplete Ph	\$1.07 h X-ray diffra taken from h n 500 subjection a missed duit cally treated synchotrons identify cancel cally treated identify cancel identify cancel identify cally treated identify cally treated iden	Timing Consider Cap'n (\$M) action in conjuncti air samples with cts were reported the to hair chemical hair may be a neg require significar require significar ers by tissue type ikelihood this mile dical practise is er Timing Consider Cap'n (\$M) ry, cosmetics, an adone (pain) (Sep adrome ny ALZA is not a 05) rcodone Q1 2008	\$153.4 on with synthe occurrent in August treatmen gative for the treatmen gative for the tot downtim e; hence m estone will ceedingly ations - N \$143.5 d nutraceut); comment positive sign	Uy and sell before tr Cash (\$M) Inchotron facilities ence of cancer t t t t t t t t t t c c t c c	ial result a \$22.6 e required \$16.30 ulin (Sept)	SI S.I		
Company • FER is devi • The theory • FER is runn • 10/14 pts w • Hair coloura • Another neg • In our view • Milestones: Comment: D Bioshares re Company • POH is con • Completed • Nestle is fu • Lack of new • Orbis Globa • Milestones: • Filing of INI • POH has s	Fermiscan Holdings eloping a breast cancer of the technology assoc ning a 2000 patient valid vere correctly identified a ation is widespread and gative for FER is its relia it is not certain that the FER expects validation eveloping a screening te commendation: Sell Phosphagenics mmercialising tocopehen Ph. I trial for TPM Insuli inding a Ph.II trial of Pho vsflow on research agre al Equity Fund holds a 1 : Complete Ph. II TPM In Ds for TPM insulin and tated that its insulin processor	Code screening te iates x-ray di lation study; as having bre an inability te ance on dedii FER techno trials to be of echnology ex Code ol (phosphor in (Aug); con ospa E in the ement (11/12 5.2 % stake nsulin in H1 2	FER chnology iffraction interim re- east cance o distingis cated bea logy can complete clusive o POH ylated vit nmencece a manage 2/05) with in POH 2008; com	CMP / based or patterns to esults from er; 4 were sh chemic am lines; si uniquely i end 2007 f evidence CMP amin E) ir d Ph. I tria ment of m n drug del (up from 7 mplete Ph ormulated	\$1.07 h X-ray diffra taken from h n 500 subjection a missed duit cally treated synchotrons identify cancel cally treated identify cancel identify cancel identify cally treated identify cally treated iden	Timing Consider Cap'n (\$M) action in conjuncti air samples with cts were reported the to hair chemical hair may be a neg require significar require significar ers by tissue type ikelihood this mile dical practise is er Timing Consider Cap'n (\$M) ry, cosmetics, an adone (pain) (Sep adrome ny ALZA is not a 05) rcodone Q1 2008	\$153.4 on with synthe occurrent in August treatmen gative for the treatmen gative for the tot downtim e; hence m estone will ceedingly ations - N \$143.5 d nutraceut); comment positive sign	Uy and sell before tr Cash (\$M) Inchotron facilities ence of cancer t t t t t t t t t t c c t c c	ial result a \$22.6 e required \$16.30 ulin (Sept)	SI S.I		
Company • FER is devi • The theory • FER is runn • 10/14 pts w • Hair coloura • Another neg • In our view • Milestones: Comment: D Bioshares re Company • POH is con • Completed • Nestle is fu • Lack of new • Orbis Globa • Milestones: • Filing of INI • POH has s Comment: H	Fermiscan Holdings eloping a breast cancer of the technology assoc ning a 2000 patient valid vere correctly identified a ation is widespread and gative for FER is its relia rit is not certain that the FER expects validation eveloping a screening to ecommendation: Sell Phosphagenics nmercialising tocopeher Ph. I trial for TPM Insuli unding a Ph.II trial of Pho vsflow on research agre al Equity Fund holds a 1 complete Ph. II TPM Ir Ds for TPM insulin and	Code screening te iates x-ray di lation study; as having bre an inability te ance on dedii FER techno trials to be of echnology ex Code ol (phosphor in (Aug); con ospa E in the ement (11/12 5.2 % stake nsulin in H1 2	FER chnology iffraction interim re- east cance o distingis cated bea logy can complete clusive o POH ylated vit nmencece a manage 2/05) with in POH 2008; com	CMP / based or patterns to esults from er; 4 were sh chemic am lines; si uniquely i end 2007 f evidence CMP amin E) ir d Ph. I tria ment of m n drug del (up from 7 mplete Ph ormulated	\$1.07 h X-ray diffra taken from h n 500 subjection a missed duit cally treated synchotrons identify cancel cally treated identify cancel identify cancel identify cally treated identify cally treated iden	Timing Consider Cap'n (\$M) action in conjuncti air samples with cts were reported the to hair chemical hair may be a neg require significar require significar rers by tissue type ikelihood this mile dical practise is ex Timing Consider Cap'n (\$M) ry, cosmetics, an adone (pain) (Sep adrome ny ALZA is not a 25) rcodone Q1 2008	stone will \$143.5 an with synthe occurrent in August treatmen gative for the treatmen in August treatmen in August in August	U and sell before tr Cash (\$M) Inchotron facilities ence of cancer It Ince FER business e for maintenance for e studies may be not be met ambitious Ione Cash (\$M) Iticals Inced Ph II TPM ins gn yrs (Sky News 21.	ial result a \$22.6 e required \$16.30 ulin (Sept)	SI S.I		

kcks with existing positive cash flows or close to producing positive cash These stocks may have more than one product or opportunity, and may even be close to market. However, they are likely to be lacking in several key areas. For example, their cash position is weak, or management or board may need strengthening. ty CMP is 20% < Fair Value Speculative Buy - Class C old Value = CMP These stocks generally have one product in development and lack many external validation features. 11 CMP is 10% > Fair Value Speculative Buy - Class A or B or C MP-Current Market Price) Sell Orporate Subscribers: Phylogica, Pharmaxis, NeuroDiscovery, Biotech Capital, Cygenics, Cytopia, Biodiem, Arana terapeutics, Starpharma Holdings, Cogstate, Xceed Biotechnology, Incitive, Optiscan Imaging, Bionomics, ChemGenex Pharma- uticals, Medical Therapies, Circadian Technologies, Biota Holdings, Stem Cell Sciences, Halcygen Pharmaceuticals, Peplin, oMD, Impedimed, QRxPharma isclaimer: formation contained in this newsletter is not a complete analysis of every material fact respecting any company, industry or security. The opinions and estimates herein expressed present the current judgement of herein (Corporations Law 849). Details contained herein have been preared for general circulation and on of have regard to any persoris or orsponsible for the preparation and publication of this report believe information herein is accurate but no warranty of accuracy is given and persons seeking to rely on information provided herein should make their own independent enquiries. At MA, ACL, ACR, BLS, BOS, B	shares	Number 244 – 7 December 2007	Page 6
<pre>get of commercialisation. In this second group, which are essend is working the preductive propositions, <i>Booknews</i> grades them according to the risk within the group, to better reflect the very large spread is within those stocks.</pre>	r the purpose of valuation of categories. The first group	on, <i>Bioshares</i> divides biotech stocks into oup are stocks with existing positive cash flows	Stocks without near term positive cash flows, history of losses, or at early stages commercialisation.
<pre>class with existing positive cash flows or close to producing positive cash w. y</pre>	ges of commercialisation lly speculative proposition ative risk within that group	n. In this second group, which are essen- ons, <i>Bioshares</i> grades them according to oup, to better reflect the very large spread	These stocks will have more than one technology, product or investment in development, with perhaps those same technologies offering multiple opportunities. These features, coupled to the presence of alliances, partnerships and scientific advisory boards,
impact of the CMP is 10% < Fair Value	roup A ocks with existing positive o ws.	cash flows or close to producing positive cash	These stocks may have more than one product or opportunity, and may even be close to market. However, they are likely to be lacking in
Mater Nume = CMP These stocks generally have one product in development and lack many extermal validation features. Setter Setter MP_Current Market Price Setter Orporate SUbscribers: Phylogica, Pharmaxis, Neurophics on Stocks generally have one product in development and lack many extermal validation features. Setter Setter Orporate SUbscribers: Phylogica, Pharmaxis, Neurophics on Stocks Genial, Cygenics, Cytopia, Biodiem, Arana terapeutics, Starpharma Holdings, Cogstate, Xeeed Biotechnology, Incitive, Optiscan Imaging, Bionomics, ChemGenex Pharma- uticals, Medical Therapies, Circadian Technologies, Biota Holdings, Stem Cell Sciences, Halcygen Pharmaceuticals, Peplin, OMD. Impedimed, QRXPharma National These stocks generally have one product in development and lack may are uticals for the product and the stocks general pharma and product in the stocks general pharma and product in development. with error Setter One State Alphane Optimics and extension stocks with error on the analysis of even material fact respecting ary company, industr or security. The optimics and extension stocks is stocks and person's or many industry or any economeration of the mole stocks are product in development and lack may and person's or many industry or any economeration whether development and person's echical person or on influence in the product and person's echical person or on inpleoi on and in the stocks is stock and person's echical person or and person's echical person and entropy is an optical person or and person in the stock and stochard and person in the stocks whether analysis is anoc	•		
pitem CMP is 10% > Fair Value many external validation features. Speculative Hold - Class A or B or C Set OrDorotet Subscribers: Phylogica, Pharmaxis, NeuroDiscovery, Biotech Capital, Cygenics, Cytopia, Biodien, Araan ierapeutics, Starpharma Holdings, Cogstate, Xeced Biotechnology, Incitive, Optiscan Imaging, Bionomics, ChemGenex Pharma- ticcals, Medical Therapies, Circadian Technologies, Biota Holdings, Stem Cell Sciences, Haleygen Pharmaceuticals, Peplin, oMD, Impedimed, QRxPharma keldiner iomation of the phylosican and any subject to change, Biate Industry and Matex Analysis PV Lid (BMA) and any of their associates, officers or saif any have present the carmon judgement of the phylosican and any subject to change, Biate Industry and Matex Analysis PV Lid (BMA) and any of their associates, officers or saif any have present the carmon judgement of the phylosican and any subject to change, Biate Industry and Matex Analysis or provide the intervent in the ownamy of accuration when any subject to change, Biate Industry and Matex Analysis or provide the intervent in the ownamy of accuration when any subject to change, Biate Industry and Matex Analysis or provide the intervent in the ownamy of accuration when any any commendation owned present engages intervent and consculate deciments and subject to change any time and are not addition of the involve and the intervent and where Corporations Law S81). The porsons involved in or responsible for the present own independent comparis is document without consulting their investment advier Corporations Law S81). The porsons involved in or responsible for the present own independent comparis is document without consulting their investment advier Corporations Law S81). The porsons involved in or responsible fore Biased and the sease pr			
11 CMP is 200% > Fair Value Speculative Hold—Class A or B or C MP-Current Market Price) Sell OrpOrate Subscribers: Phylogica, Pharmaxis, NeuroDiscovery, Biotech Capital, Cygenics, Cytopia, Biodiem, Arana icclass, Medical Therapies, Circadian Technologies, Biota Holdings, Stem Cell Sciences, Haleygen Pharmaceuticals, Peplin, oMD, Impedimed, QRXPharma isclamer formation contained in this newdater is not a complete analysis of every material fact respecting any company, industry or security. The opinions and estimates herein expressed present the current judgement of the pathiater and are subject to change, Bible Holdings, Nem prepard for general circulation and do not have regard to any present's or entires in securities end before: (Corporations Law s 349). Deails contained herein have been provided by the subscription of the pathiater and and subject to change, Accordingly, on recipients should evel on any accouncil whether or spress of implicit or antion on the basis here and ys and persons seeking to retry on antifere the investment adviser (Corporations Law s 459). Deails contained herein have been provided by this header and biotechnology to velom the have been provided by this header and biotechnology to velom they have been provided by this header and biotechnology or scrifts. AAH, ACL, RE, BLS, BOS, BTA, COS, CYT, CVK V1.4. Dereversion and advector is a complete analysis of every material fact header and biotechnology is used to have been provided by this header and biotechnology or scrifts. AAH, ACL, ACL, BLS, BOS, BTA, COS, CYT, CVK, VY, LVB, ID, These morestros and have been provided by this header and the the well advecases of the same business cost centre, our S500 e-10 maint addressees V1.4. <td></td> <td></td> <td></td>			
proprate Subscribers: Phylogica, Pharmaxis, NeuroDiscovery, Biotech Capital, Cygenics, Cytopia, Biodiem, Arana herapeutics, Starpharma Holdings, Cogstate, Xceed Biotechnology, Incitive, Optiscan Imaging, Bionomics, ChemGenex Pharma- uicals, Medical Therapies, Circadian Technologies, Biota Holdings, Stem Cell Sciences, Halcygen Pharmaceuticals, Peplin, oMD, Impedimed, QRXPharma inclusion formation contained in this newslerr is not a complete analysis of very material fact respecting any company, industry or security. The opinions and estimates berein expressed present the current plagment of the publisher and are subject to change. Blake Industry and Market Analysis Py Lot (BIAA) and yor their associates, officers or saff may have resets in securities (SAR). The provide starbard and or their expression or sufficient in supersents or sufficient or expression in the entry independent consulting their insecure to objectives, financial stratuton and particular needs. Accordingly, no recipients should rely on any recommendation (whether express or implied) contained in subout make their own independent enguires. is channel without constrain there in have been associates declare interests in the following ASX Healthcare and Biotechnology sector securities: AAH, ACL, ACR, BLS, BOS, BTA, CGS, CYT, CUV, SK, NLY, MBP, RAP, PLP, PL, PCL, PXS, SHC, SPL, TBCUB. These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less than 00 are not disclosed. Subscription Rates (inc. GST) 45 (structure is as follows: \$950 6-10 email addresses yttel, HD proces a cheque for \$ made payable to Blake Industry anal addresseses <td< td=""><td>CMP is 209</td><td></td><td>-</td></td<>	CMP is 209		-
erapeutics, Starpharma Holdings, Cogstate, Xcced Biotechnology, Incitive, Optiscan Imaging, Bionomics, ChemGenex Pharmacuticals, Medical Therapies, Circadian Technologies, Biota Holdings, Stem Cell Sciences, Halcygen Pharmaceuticals, Peplin, oMD, Impedined, QRXPharma Istainer: Tomation contained in this newsletter is not a complete analysis of every material fact respecting any company, industry or security. The optinions and estimates herein expressed preser the carenel polysites, financial stuaturo and protein balace ladausy and Mariet Analysis Pty Lid (BIMA) and any of the polysites frame analysis of every material fact respecting any company, industry or security. The optinions and estimates herein expressed preser the carenel polysites, financial stuaturo and protein parson secking to rely on information provided benchmer expersit of any presors or major's investment bare to avain any of accuracy is given and presons secking to rely on information provided benchmer expersite and market Analysis pty Lid. (BLA) And any of there associates, office any presors or major's investment have been issued on the basis they are only for the pariotal persons or company to have the have been provided by their heave induced market. Accuracy is given and presons secking to rely on information provided benchmer expersite and market Analysis pty Lid. (BLA) ANAL, PLI, PCL, PXS, SHC, SHT, TISUBI. These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less that 00 are not disclosed. MEMERSING THE CALL ACR, BLS, BOS, BTA, CCS, CYT, CUY, SK, SHX, MBP, AP, PLI, PCL, PXS, SHC, SHT, TISUBI. These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less that 00 are not disclosed. MEMERSING THE CALL ACR, BLS, BOS, BTA, CCS, CYT, CUY, SK, SHX, MBP, AP, PLI, PCL, PXS, SHC, SHT, TISUBI. These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less that 00 are not disclosed. MEMERSIN		·	
formation contained in this news/letter is not complete analysis of every material fact respecting any company, indury or security. The opinions and estimates beerin expressed present discurse softener to brefin. (Corporations Law s.849). Details contained herein have been provided by entry or commendation (whether expressed in particular needs). Coordination and persons is evolutions of persons involved in or responsibility of the investment advisor (Corporations Law s.841). The persons involved in or responsibility of the the pericular and periods seture is a counter but no warrang of accuracy is given and persons seturity to person or company to whom they have been provided by false fadausty and Market Analysis (Law SAN). The persons involved in or responsibility of the investment advisor (Corporations Law s.841). The persons involved in or responsibility of the investment advisor (Corporations Law s.841). The persons involved in or responsibility of the investment advisor (Corporations Law s.841). The persons involved in or responsibility of the investment advisor (Corporations Law s.841). The persons involved in or responsibility of the investment advisor (Corporations Law s.841). The persons involved in or responsibility of the investment advisor advisor and persons is evolved and persons is evolved and persons involved in our persons involved in our independent equiparies of the person involved in the persons involved in per	nerapeutics, Starpharm uticals, Medical Thera	a Holdings, Cogstate, Xceed Biotechnolo pies, Circadian Technologies, Biota Hold	gy, Incitive, Optiscan Imaging, Bionomics, ChemGenex Pharma-
48 issues per year (electronic distribution): \$320 For multiple email distributions within \$550 2-3 email addresses the same business cost centre, our \$750 4-5 email addresses pricing structure is as follows: \$950 6-10 email addresses To subscribe, post/fax this subscription form to: Bioshares PO Box 193 Richmond VIC 3121 Fax: 61 3 9671 3633 I enclose a cheque for \$ made payable to Blake Industry & Market Analysis Pty Ltd, or Please charge my credit card \$ MasterCard Visa Card Number	ompany's investment objectives is document without consulting the information herein is accurat etails contained herein have been ty Ltd. The Directors and/or ass	, financial situation and particular needs. Accordingly, no their investment adviser (Corporations Law s.851). The p e but no warranty of accuracy is given and persons seek en issued on the basis they are only for the particular pers ociates declare interests in the following ASX Healthcare a	recipients should rely on any recommendation (whether express or implied) contained in bersons involved in or responsible for the preparation and publication of this report believe ing to rely on information provided herein should make their own independent enquiries. on or company to whom they have been provided by Blake Industry and Market Analysis ind Biotechnology sector securities: AAH, ACL, ACR, BLS, BOS, BTA, CGS, CYT, CUV,
the same business cost centre, our pricing structure is as follows: \$750 4-5 email addresses Store \$950 6-10 email addresses To subscribe, post/fax this subscription form to: Bioshares PO Box 193 Richmond VIC 3121 Fax: 61 3 9671 3633 I enclose a cheque for \$ made payable to Blake Industry & Market Analysis Pty Ltd, or Please charge my credit card \$ MasterCard Visa Card Number Expiry date Signature		_ 48 issues per year (elect	ronic distribution): \$320
PO Box 193 Richmond VIC 3121 Fax: 61 3 9671 3633 I enclose a cheque for \$ made payable to Blake Industry & Market Analysis Pty Ltd, or Please charge my credit card \$ MasterCard Visa Card Number		the same business cost centre, our	\$750 4-5 email addresses
Please charge my credit card \$ MasterCard Visa Card Number	To subscribe, pos	•	PO Box 193 Richmond VIC 3121
Card Number Signature Subscriber details Name Organisation Ph ()	I enclose a cheq	ue for \$ made payable to I	Blake Industry & Market Analysis Pty Ltd, or
Signature Subscriber details Name Organisation Ph ()	Please charge m	y credit card \$ Master	Card 🗌 Visa 🗌
Subscriber details Name Organisation Ph ()	Card Number		
Name	Signature		Expiry date
Organisation Ph ()	Subscriber de	etails	
Ph ()	Name		
	Organisation		
Emails	Ph ()		
	Emails		